Please assess the completion status of the following clinical trial:

Trial Title: Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Myelodysplastic Syndrome by FAB. Can be made with cytogenetic analysis of Bone Marrow or Hematologist evaluation~* Patient must have had bone marrow biopsy and aspiration to confirm diagnosis within 60 days prior to treatment~* ECOG performance status of 0-2~* An EKG must be performed within 7 days prior to treatment to confirm QT interval \<460msec.~* Serum creatinine less than or equal to 2.5 times the upper limit of normal.~* Serum bilirubin less than or equal to 2.5 times the upper limit of normal.~* Serum potassium greater than or equal to 4.0 mEq/dL and serum magnesium greater than or equal to 1.8 mg/dL. If these serum electrolytes are below the specified limits on the baseline laboratory tests, electrolytes should be administered to bring the serum concentrations to these levels before administering arsenic trioxide.~* Patients must be 18 years of age to participate in this study~Exclusion Criteria:~* Pregnant or nursing women, and men or women of childbearing potential who are unwilling to employ adequate contraception.~* Corrected QT interval of greater than or equal to 460msec in the presence of serum potassium and magnesium values within normal range.~* Significant CHF, coronary is ischemia or serious Arrhythmias including conduction delays.~* Peripheral neuropathy greater than or equal to 2.~* Evidence of active infection~* Concurrent treatment with maintenance therapy, cytotoxic chemotherapy, radiation, or investigational agents.~* Inability or unwillingness to comply with the treatment protocol, follow up, or research tests.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).